Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 4,540,000 shares, a drop of 17.5% from the December 31st total of 5,500,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is presently 3.5 days.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. UBS Group decreased their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday. HC Wainwright lowered their price objective on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. Wedbush reissued a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Wells Fargo & Company lowered their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday. Finally, Guggenheim cut their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.24.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ZNTL. American Century Companies Inc. acquired a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $95,000. Bank of Montreal Can acquired a new position in Zentalis Pharmaceuticals during the second quarter worth $402,000. Squarepoint Ops LLC increased its holdings in Zentalis Pharmaceuticals by 543.8% during the second quarter. Squarepoint Ops LLC now owns 148,755 shares of the company’s stock worth $608,000 after buying an additional 125,649 shares during the last quarter. Algert Global LLC bought a new stake in Zentalis Pharmaceuticals during the second quarter worth $78,000. Finally, SG Americas Securities LLC lifted its stake in Zentalis Pharmaceuticals by 84.8% in the third quarter. SG Americas Securities LLC now owns 26,149 shares of the company’s stock valued at $96,000 after acquiring an additional 11,997 shares during the last quarter.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $1.74 on Friday. The business has a 50-day moving average of $2.94 and a 200-day moving average of $3.27. Zentalis Pharmaceuticals has a fifty-two week low of $1.66 and a fifty-two week high of $18.07. The stock has a market capitalization of $124.00 million, a P/E ratio of -0.70 and a beta of 1.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.36. Equities analysts expect that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.